Grace Therapeutics, Inc. news GRCE
Plain-English coverage of this company’s material 8-K filings — generated from the primary source the moment they file.
← back to Grace Therapeutics, Inc.-
High Negative
Grace Therapeutics Reports $7.8M Net Loss; FDA Meeting Scheduled on GTx-104
The biopharma firm faces FDA manufacturing questions on its aneurysmal hemorrhage candidate but plans to resubmit after clarification meeting.